Compare GPRE & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | SPRY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 788.5M |
| IPO Year | 2004 | 2020 |
| Metric | GPRE | SPRY |
|---|---|---|
| Price | $14.91 | $9.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $12.57 | ★ $40.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,091,680,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $11.85 | $81.64 |
| P/E Ratio | $35.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.63 | $6.66 |
| 52 Week High | $18.94 | $18.63 |
| Indicator | GPRE | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 60.95 |
| Support Level | $14.64 | $9.50 |
| Resistance Level | $15.64 | $10.44 |
| Average True Range (ATR) | 0.65 | 0.61 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 28.41 | 88.42 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.